Innovative Eyewear, Inc. (LUCY)
NASDAQ:LUCY
Want to see LUCY full AI Analyst Report?
Top Page
Innovative Eyewear, Inc.
(NASDAQ:LUCY)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.98
▼(-7.55% Downside)
Action:Reiterated
Date:05/15/26
The score is held down primarily by weak financial performance (large ongoing losses and volatile/uncertain cash flow quality despite improving revenue and positive gross margin) and bearish technical positioning (below major moving averages with negative MACD). Valuation cannot be meaningfully supported from the provided P/E and missing dividend yield data, further limiting upside in the score.
Positive Factors
Strong multi-year revenue growth
Consistent multi-year top-line expansion (62.65% growth to ~$2.98M TTM) indicates product-market traction in smart eyewear. Durable revenue growth creates room to scale fixed costs, supports distribution expansion, and underpins longer-term profitability if unit economics continue improving.
Negative Factors
Persistent large operating and net losses
Deep and ongoing operating and net losses mean the company has not yet scaled cost structure to revenue. Over the medium term this necessitates continued external funding or material margin improvement; persistent losses limit reinvestment capacity and raise dilution and execution risk for the business model.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong multi-year revenue growth
Consistent multi-year top-line expansion (62.65% growth to ~$2.98M TTM) indicates product-market traction in smart eyewear. Durable revenue growth creates room to scale fixed costs, supports distribution expansion, and underpins longer-term profitability if unit economics continue improving.
Read all positive factors
Innovative Eyewear, Inc. (LUCY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.53M
Dividend YieldN/A
Average Volume (3M)543.31K
Price to Earnings (P/E)―
Beta (1Y)2.06
Revenue Growth74.57%
EPS Growth60.81%
CountryUS
Employees11
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-1.75
Shares Outstanding6,403,728
10 Day Avg. Volume196,778
30 Day Avg. Volume543,314
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.44
Price to Sales (P/S)1.49
P/FCF Ratio-0.54
Enterprise Value/Market Cap-0.04
Enterprise Value/Revenue-0.09
Enterprise Value/Gross Profit-0.49
Enterprise Value/Ebitda0.03
Forecast
1Y Price Target
$3.00Price Target Upside183.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.03
Revenue Forecast (FY)$9.00M
Innovative Eyewear, Inc. Business Overview & Revenue Model
Company Description
Innovative Eyewear, Inc. develops and sells smart eyeglasses and sunglasses. The company's flagship product is Lucyd Lyte glasses that enable the wearer to listen to music, take and make calls, and use voice assistants to perform various smartphon...
How the Company Makes Money
null...
Innovative Eyewear, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
46
Neutral
Cash Flow
32
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.98M | 2.66M | 1.64M | 1.15M | 659.79K | 690.67K |
| Gross Profit | 522.36K | 567.45K | 215.19K | -119.33K | -56.29K | 148.25K |
| EBITDA | -8.83M | -8.36M | -7.62M | -6.58M | -5.54M | -3.20M |
| Net Income | -8.12M | -7.59M | -7.77M | -6.66M | -5.68M | -3.24M |
Balance Sheet | ||||||
| Total Assets | 9.48M | 10.14M | 9.84M | 6.22M | 4.69M | 824.32K |
| Cash, Cash Equivalents and Short-Term Investments | 5.68M | 6.51M | 7.52M | 4.29M | 3.59M | 79.73K |
| Total Debt | 52.61K | 0.00 | 0.00 | 0.00 | 61.36K | 289.03K |
| Total Liabilities | 1.11M | 1.07M | 743.17K | 659.94K | 665.46K | 616.80K |
| Stockholders Equity | 8.37M | 9.07M | 9.10M | 5.56M | 4.02M | 207.52K |
Cash Flow | ||||||
| Free Cash Flow | -7.64M | -7.35M | -7.01M | -6.02M | -3.44M | -1.33M |
| Operating Cash Flow | -7.45M | -7.28M | -6.74M | -5.77M | -3.22M | -1.21M |
| Investing Cash Flow | -1.51M | 4.48M | -5.16M | -198.75K | -219.95K | -118.45K |
| Financing Cash Flow | 8.08M | 6.68M | 10.24M | 6.66M | 6.96M | 1.39M |
Innovative Eyewear, Inc. Technical Analysis
Neutral
1.06
Price Trends
1.06
Negative
1.14
Negative
1.45
Negative
Market Momentum
-0.02
Negative
50.59
Neutral
66.38
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LUCY, the sentiment is Neutral. The current price of 1.06 is above the 20-day moving average (MA) of 1.01, above the 50-day MA of 1.06, and below the 200-day MA of 1.45, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 50.59 is Neutral, neither overbought nor oversold. The STOCH value of 66.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for LUCY.
Innovative Eyewear, Inc. Risk Analysis
Innovative Eyewear, Inc. disclosed 40 risk factors in its most recent earnings report. Innovative Eyewear, Inc. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Innovative Eyewear, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $3.08B | 204.66 | 0.37% | ― | 12.01% | ― | |
58 Neutral | $1.62B | 48.44 | -6.07% | ― | 4.03% | 70.55% | |
56 Neutral | $5.68B | -19.89 | -3.41% | ― | 7.85% | 39.85% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $21.35M | -1.17 | -8.13% | ― | 10.08% | 71.71% | |
44 Neutral | $6.53M | -0.74 | -74.10% | ― | 74.57% | 60.81% |
* Healthcare Sector Average
LUCY
Innovative Eyewear, Inc.
1.02
-1.83
-64.21%
RVP
Retractable Technologies
0.71
0.06
9.86%
STAA
Staar Surgical
32.47
13.79
73.82%
WRBY
Warby Parker
25.09
4.50
21.86%
BLCO
Bausch + Lomb Corporation
15.92
4.63
41.01%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.